Free tool
FAERS Monitor: Vocabria
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212887 or its brand name (Vocabria, Cabotegravir Sodium). Reports on generic versions are filed under their own applications.
Reports
1,605
Serious
1,144
71% of reports
Hospitalization
219
Death reported
89
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- viral load increased110
- injection site pain109
- product dose omission issue89
- virologic failure66
- hepatitis b65
- off label use64
- pathogen resistance61
- nausea58
- fatigue57
- headache56
- inappropriate schedule of product administration56
- hepatitis b reactivation54
- rash52
- malaise49
- blood hiv rna increased48
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 82 |
| 2022 | 339 |
| 2023 | 364 |
| 2024 | 313 |
| 2025 | 330 |
| 2026 | 168 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| viral load increasedSignal | 110 | 382.1 | 318.2 | 40,267 |
| blood hiv rna increasedSignal | 48 | 356.3 | 268.6 | 16,215 |
| hepatitis b reactivationSignal | 54 | 226.8 | 174.1 | 11,714 |
| virologic failureSignal | 66 | 162.8 | 128.4 | 10,328 |
| hepatitis bSignal | 65 | 142.9 | 112.5 | 8,922 |
| pathogen resistanceSignal | 61 | 88.3 | 69.0 | 5,145 |
| injection site painSignal | 109 | 4.7 | 3.9 | 314 |
| inappropriate schedule of product administrationSignal | 56 | 4.1 | 3.1 | 128 |
| product dose omission issueSignal | 89 | 4.0 | 3.2 | 197 |
| rash | 52 | 1.6 | 1.2 | 10 |
| malaise | 49 | 1.5 | 1.1 | 7 |
| headache | 56 | 1.2 | 0.9 | 1 |
| nausea | 58 | 1.0 | 0.7 | 0 |
| fatigue | 57 | 1.0 | 0.7 | 0 |
| off label use | 64 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.